Nicholas Bacopoulos - Cyclacel Pharmaceuticals Independent Director


USD 0.84  0.01  1.20%   

Dr. Nicholas G. Bacopoulos Ph.D. is an Independent Director of Cyclacel Pharmaceuticals Inc. Dr. Bacopoulos joined the Board of Directors of Cyclacel in September 2008. He is currently the Chief Executive Officer of Mersana Therapeutics a private biotechnology company. Prior to that Mr. Bacopoulos was a consultant to biotech and pharmaceutical companies. His previous leadership roles include Chief Executive Officer and President of Aton Pharma Inc. where he led the development of Zolinza approved for the treatment of cutaneous Tcell lymphoma. Aton was subsequently acquired by Merck Co. Inc. He was previously President and Head of Research and Development at OSI Pharmaceuticals Inc. where he was involved with the global development of Tarceva approved for the treatment of nonsmall cell lung cancer and pancreatic cancer. Dr. Bacopoulos also worked for 17 years at Pfizer where he held senior positions within Pfizer Central Research and Corporationrationrate Strategic Planning. He led the companys Cancer and Neuroscience Research groups which developed several marketed drugs including Geodon and Zoloft and produced a pipeline of oncology drug candidates several of which are in clinical trials
Age: 64  Director Since 2008  Ph.D    
908 517 7330
Bacopoulos also serves on the board of directors of Mersana Therapeutics, Inc. and Medexis Biotech, S.A., both privatelyheld biotechnology companies. He received his B.A. degree from Cornell College and his Ph.D. from the University of Iowa. He completed additional coursework and obtained a postdoctoral fellowship at Yale University School of Medicine.

Cyclacel Pharmaceuticals Management Efficiency

Cyclacel Pharmaceuticals has return on total asset (ROA) of (0.4167) % which means that it has lost $0.4167 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.6014) %, meaning that it created substantial loss on money invested by shareholders. Cyclacel Pharmaceuticals management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 113 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Cyclacel Pharmaceuticals has a current ratio of 6.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Cyclacel Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Cyclacel Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cyclacel Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cyclacel to invest in growth at high rates of return. When we think about Cyclacel Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 13 records


Mary CitrinoHP Inc
Stephanie BurnsHP Inc
Rajiv GuptaHP Inc
Chip BerghHP Inc
James SkinnerHP Inc
Yoky MatsuokaHP Inc
Aida AlvarezHP Inc
Stacey MobleyHP Inc
Shumeet BanerjiHP Inc
Carl BassHP Inc
Stacy BrownPhilpotHP Inc
Robert BennettHP Inc
Subra SureshHP Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Cyclacel Pharmaceuticals (CYCC) is traded on NASDAQ Exchange in USA and employs 14 people. Cyclacel Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Cyclacel Pharmaceuticals Leadership Team

Elected by the shareholders, the Cyclacel Pharmaceuticals' board of directors comprises two types of representatives: Cyclacel Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyclacel. The board's role is to monitor Cyclacel Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cyclacel Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyclacel Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Gill Christie, Director HR
Samuel Barker, Director
Christopher Henney, Independent Vice Chairman of the Board
Gregory Hradsky, Independent Director
John Banham, Independent Director
Robert Westwood, Head Devel
Paul McBarron, COO, CFO, Principal Accounting Officer, Executive VP of Fin. and Admin., Secretary and Executive Director
Nicholas Bacopoulos, Independent Director
Lloyd Sems, Independent Director
David UPrichard, Independent Chairman of the Board
Judy Chiao, Vice President - Clinical Development and Regulatory Affairs
Mark MD, VP Officer
Robert Spiegel, Independent Director
Spiro Rombotis, CEO and President and Executive Director

Cyclacel Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyclacel Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cyclacel Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Rebalancing Now


Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Pair Trading with Cyclacel Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclacel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Cyclacel Pharmaceuticals

-0.66RETAReata Pharmaceuticals Normal TradingPairCorr
-0.6JPMJPMorgan Chase Fiscal Year End 13th of January 2023 PairCorr
The ability to find closely correlated positions to Cyclacel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclacel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclacel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclacel Pharmaceuticals to buy it.
The correlation of Cyclacel Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclacel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclacel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclacel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Cyclacel Pharmaceuticals information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuticals price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Is Cyclacel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
10.1 M
Return On Assets
Return On Equity
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Cyclacel Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.